Peramivir

Kathryn Dzintars, Pharm.D., BCPS, Paul A. Pham, Pharm.D. BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • FDA approved for uncomplicated influenza in patients 2 years and older with symptoms present less then 2 days.

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Treatment of influenza for hospitalized adult and pediatric patients for whom therapy with an IV anti-influenza drug is needed.
    • Limited data available to support efficacy in complicated influenza, or influenza requiring hospitalization or influenza > 48h duration[7].
    • Peramivir can be considered for treatment failure occurring with use of currently approved anti-influenza drugs (e.g., oseltamivir and zanamivir) and in patients who are unable to take oral or inhaled anti-viral therapy.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.